Use of mullerian inhibiting substance for treating excess androgen states

• US 20040062750A1
• Filed: 10/10/2003
• Published: 04/01/2004
• Est. Priority Date: 09/14/1999
• Status: Abandoned Application

• Current Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Inventors: Fynn-Thompson, Eric, Teixeira, Jose, Donahoe, Patricia K.
• Application Number:
  US10/683,346
• Publication Number:
  US 20040062750A1
• Time in Patent Office: Days
• US Class Current: 424/85.1
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

The present invention provides a method of treating a condition or disease characterized by an excess of one or more androgens, the method comprising administering an effective amount of MIS protein or nucleic acid encoding MIS to a patient. The present invention also provides a method of decreasing the level of one or more androgens to a level below the normal level, the method comprising administering an effective amount of MIS protein or nucleic acid encoding MIS to a patient. The methods of the present invention are particularly well-suited for the treatment of prostatic cancer, polycystic ovarian disease, benign prostatic hypertrophy, and precocious puberty.

Claims

1. A method of treating a condition or disease characterized by an excess of one or more androgens, said method comprising administering an effective amount of MIS to a patient.

2. The method of claim 1, wherein said one or more androgens is testosterone.

3. The method of claim 1, wherein said MIS has a molecular weight of about 140 kDa or about 70 kDa.

4. The method of claim 1, wherein said MIS is the C-terminal fragment of MIS.

5. The method of claim 3, wherein said C-terminal fragment has a molecular weight of about 25 kDa or about 12.5 kDa.

6. The method of claim 1, wherein said condition or disease is selected from the group consisting of polycystic ovarian disease and precocious puberty.

7. The method of claim 6, wherein said condition or disease is polycystic ovarian disease.

8. The method of claim 6, wherein said condition or disease is precocious puberty.

9. A method of treating a condition or disease characterized by an excess of one or more androgens, said method comprising administering an effective amount of a nucleic acid encoding MIS to a patient.

10. The method of claim 9, wherein said one or more androgens is testosterone.

11. The method of claim 9, wherein said MIS has a molecular weight of about 140 kDa or about 70 kDa.

12. The method of claim 9, wherein said MIS is the C-terminal fragment of MIS.

13. The method of claim 12, wherein said C-terminal fragment has a molecular weight of about 25 kDa or about 12.5 kDa.

14. The method of claim 9, wherein said condition or disease is selected from the group consisting of polycystic ovarian disease and precocious puberty.

15. The method of claim 14, wherein said condition or disease is polycystic ovarian disease.

16. The method of claim 14, wherein said condition or disease is precocious puberty.

17. A method of decreasing the plasma level of one or more androgens, said method comprising administering to a patient an effective amount of MIS, wherein said amount of MIS is sufficient to decrease the plasma level of said one or more androgens below the normal level for said one or more androgens.

18. The method of claim 17, wherein said one or more androgens is testosterone.

19. The method of claim 17, wherein said MIS has a molecular weight of about 140 kDa or about 70 kDa.

20. The method of claim 17, wherein said MIS is the C-terminal fragment of MIS.

21. The method of claim 20, wherein said C-terminal fragment has a molecular weight of about 25 kDa or about 12.5 kDa.

22. The method of claim 17, wherein said patient has benign prostatic hypertrophy, and wherein as a result of the administration of said MIS, the extent of said hypertrophy is diminished.

23. The method of claim 17, wherein said patient has prostate cancer, and wherein as a result of the administration of said MIS, the progression of said cancer is halted or slowed.

24. A method of decreasing the plasma level of one or more androgens, said method comprising administering to a patient an effective amount of nucleic acid encoding MIS, wherein said amount of MIS is sufficient to decrease the plasma level of said one or more androgens below the normal level for said one or more androgens.

25. The method of claim 24, wherein said one or more androgens is testosterone.

26. The method of claim 24, wherein said MIS has a molecular weight of about 140 kDa or about 70 kDa.

27. The method of claim 24, wherein said MIS is the C-terminal fragment of MIS.

28. The method of claim 27, wherein said C-terminal fragment has a molecular weight of about 25 kDa or about 12.5 kDa.

29. The method of claim 24, wherein said patient has benign prostatic hypertrophy, and wherein as a result of the administration of said nucleic acid, the extent of said hypertrophy is diminished.

30. The method of claim 24, wherein said patient has prostate cancer, and wherein as a result of the administration of said nucleic acid, the progression of said cancer is halted or slowed.